Results 41 to 50 of about 797,089 (324)

Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy [PDF]

, 2018
Background: Fibrosis may be considered the hallmark of systemic sclerosis (SSc), the end stage triggered by different pathological events. Transforming growth factor-β (TGF-β) and platelet-derived growth factor BB (PDGF-BB) are profibrotic molecules ...
Berardicurti O., Carubbi F., Ciccia F., Cipriani P., Di Bartolomeo S., Di Benedetto P., Giacomelli R., Guggino G., Liakouli V., Panzera N., Ruscitti P., Triolo G.   +11 more
core   +1 more source

Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers [PDF]

, 2014
Background: DNA-dependent protein kinase catalytic subunit (DNA-PKcs), a serine threonine kinase belonging to the PIKK family (phosphoinositide 3-kinase-like-family of protein kinase), is a critical component of the non-homologous end joining (NHEJ ...
AC Wolff, Andrew R. Green, Arvind Arora, B Salles, C Curtis, Christina Perry, Devika Agarwal, Emad Rakha, ET Shinohara, FM Hsu, Graham Ball, HS Lee, HS Lee, Ian O. Ellis, JA Neal, K Meek, K Soderlund Leifler, L Du, LA Loeb, LA Loeb, LM McShane, M Burg van der, Nicola Thompson, Paul Moseley, R Hill, R Sultana, S Medunjanin, SJ Collis, SL Shao, Srinivasan Madhusudan, Stephen Chan, SY Wang, Tarek Abdel-Fatah, TM Abdel-Fatah, TM Abdel-Fatah, TM Abdel-Fatah, U Moll, W Zhuang, X Kong, X Wang, XD Long, Z Hu   +41 more
core   +1 more source

Anti-Inflammatory Therapy for Temporomandibular Joint Osteoarthritis Using mRNA Medicine Encoding Interleukin-1 Receptor Antagonist

Pharmaceutics, 2022
Messenger RNA (mRNA) is an emerging drug modality for protein replacement therapy. As mRNA efficiently provides protein expression in post-mitotic cells without the risk of insertional mutagenesis, direct delivery of mRNA can be applied, not only as an ...
Jia Deng, Yuta Fukushima, Kosuke Nozaki, Hideyuki Nakanishi, Erica Yada, Yuki Terai, Kenji Fueki, Keiji Itaka   +7 more
doaj   +1 more source

Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle

Bioactive Materials, 2020
mRNA is a novel class of therapeutic modality that holds great promise in vaccination, protein replacement therapy, cancer immunotherapy, immune cell engineering etc.
Tongren Yang, Chunhui Li, Xiaoxia Wang, Deyao Zhao, Mengjie Zhang, Huiqing Cao, Zicai Liang, Haihua Xiao, Xing-Jie Liang, Yuhua Weng, Yuanyu Huang   +10 more
doaj   +1 more source

Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment

Journal for ImmunoTherapy of Cancer, 2023
Background Personalized mRNA vaccines are promising new therapeutic options for patients with cancer. Because mRNA vaccines are not yet approved for first-line therapy, the vaccines are presently applied to individuals that received prior therapies that ...
Dietmar Zehn, Michael Aigner, Lara Victoria Donhauser, Julia Veloso de Oliveira, Cordula Schick, Wenzel Manlik, Sabrina Styblova, Sarah Lutzenberger, Patrick Philipp, Sebastian Robert, Beate Gandorfer, Dirk Hempel, Louisa Hempel   +12 more
doaj   +1 more source

Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. [PDF]

, 1990
BALB/c mice infected with Leishmania major develop fatal, progressive disease, despite an immune response characterized by expansion of CD4+ T cells in the draining lymph nodes.
Dawkins, RS, Heinzel, FP, Holaday, BJ, Locksley, RM, Pu, RT, Sadick, MD   +5 more
core   +1 more source

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Annals of the Rheumatic Diseases, 2021
Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become a high priority. Persons at risk of severe disease, for example, those receiving immunosuppressive therapies for chronic inflammatory cdiseases (CIDs), are ...
U. Geisen, D. Berner, F. Tran, M. Sümbül, L. Vullriede, M. Ciripoi, H. M. Reid, Annika Schaffarzyk, A. Longardt, J. Franzenburg, P. Hoff, J. Schirmer, R. Zeuner, A. Friedrichs, Andrea Steinbach, C. Knies, R. Markewitz, P. J. Morrison, S. Gerdes, S. Schreiber, B. Hoyer   +20 more
semanticscholar   +1 more source

Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics

Molecular Therapy: Methods & Clinical Development, 2018
New treatments to overcome the obstacles of conventional anti-cancer therapy are a permanent subject of investigation. One promising approach is the application of toxins linked to cell-specific ligands, so-called immunotoxins.
Kristin Hirschberger, Anita Jarzebinska, Eva Kessel, Verena Kretzschmann, Manish K. Aneja, Christian Dohmen, Annika Herrmann-Janson, Ernst Wagner, Christian Plank, Carsten Rudolph   +9 more
doaj   +1 more source

Relative expression of IL-10 and TNF-α mRNA of kidney and spleen tissues of rat with and without mammary tumor after exposed to alternating current electric field

Acta Biochimica Indonesiana, 2023
Background: Cancer therapy based on alternating current electric field exposure, Electro-Capacitive Cancer Therapy (ECCT), has been pre-clinically tested for its effectiveness in breast tumor inhibition.
Nafisa Khoirun Widiasri, Anysah Nur Fauziyah, Firman Alamsyah, Rarastoeti Pratiwi   +3 more
doaj   +1 more source

The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review

Frontiers in Immunology, 2022
Both infectious viral diseases and cancer have historically been some of the most common causes of death worldwide. The COVID-19 pandemic is a decidedly relevant example of the former. Despite progress having been made over past decades, new and improved
Reese Jalal Ladak, Reese Jalal Ladak, Alexander J. He, Yu-Hsun Huang, Yu Ding   +4 more
doaj   +1 more source